Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors - PubMed

Affiliations

• PMID: 34000808
• DOI: 10.1021/acs.jmedchem.1c00325

Review

Glutaminyl Cyclase, Diseases, and Development of Glutaminyl Cyclase Inhibitors

Chenshu Xu et al. J Med Chem. 2021.

Abstract

Pyroglutamate (pE) modification, catalyzed mainly by glutaminyl cyclase (QC), is prevalent throughout nature and is particularly important in mammals including humans for the maturation of hormones, peptides, and proteins. In humans, the upregulation of QC is involved in multiple diseases and conditions including Alzheimer's disease, Huntington's disease, melanomas, thyroid carcinomas, accelerated atherosclerosis, septic arthritics, etc. This upregulation catalyzes the generation of modified mediators such as pE-amyloid beta (Aß) and pE-chemokine ligand 2 (CCL2) peptides. Not surprisingly, QC has emerged as a reasonable target for the development of therapeutics to combat these diseases and conditions. In this manuscript the deleterious effects of upregulated QC resulting in disease manifestation are reviewed, along with progress on the development of QC inhibitors.

Similar articles

• Immunohistochemical Evidence from APP-Transgenic Mice for Glutaminyl Cyclase as Drug Target to Diminish pE-Abeta Formation.

  Hartlage-Rübsamen M, Bluhm A, Piechotta A, Linnert M, Rahfeld JU, Demuth HU, Lues I, Kuhn PH, Lichtenthaler SF, Roßner S, Höfling C. Hartlage-Rübsamen M, et al. Molecules. 2018 Apr 17;23(4):924. doi: 10.3390/molecules23040924. Molecules. 2018. PMID: 29673150 Free PMC article.

• Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms.

  Hartlage-Rübsamen M, Morawski M, Waniek A, Jäger C, Zeitschel U, Koch B, Cynis H, Schilling S, Schliebs R, Demuth HU, Rossner S. Hartlage-Rübsamen M, et al. Acta Neuropathol. 2011 Jun;121(6):705-19. doi: 10.1007/s00401-011-0806-2. Epub 2011 Feb 8. Acta Neuropathol. 2011. PMID: 21301857 Free PMC article.

• An overview of glutaminyl cyclase inhibitors for Alzheimer's disease.

  Coimbra JR, Sobral PJ, Santos AE, Moreira PI, Salvador JA. Coimbra JR, et al. Future Med Chem. 2019 Dec;11(24):3179-3194. doi: 10.4155/fmc-2019-0163. Future Med Chem. 2019. PMID: 31838899 Review.

• Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology.

  Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, Schlenzig D, Lindner C, Rudolph T, Reuter G, Cynis H, Montag D, Demuth HU, Rossner S. Schilling S, et al. Nat Med. 2008 Oct;14(10):1106-11. doi: 10.1038/nm.1872. Epub 2008 Sep 28. Nat Med. 2008. PMID: 18836460

• Glutaminyl cyclases, the potential targets of cancer and neurodegenerative diseases.

  Zhang Y, Wang Y, Zhao Z, Peng W, Wang P, Xu X, Zhao C. Zhang Y, et al. Eur J Pharmacol. 2022 Sep 15;931:175178. doi: 10.1016/j.ejphar.2022.175178. Epub 2022 Aug 7. Eur J Pharmacol. 2022. PMID: 35948163 Review.

Cited by

• Increased QPCT gene expression by the hepatitis B virus promotes HBV replication.

  Zhang C, Ma Q, Wang W, Song H, Wang X, Xu F, Zhu C, Liu X. Zhang C, et al. PLoS One. 2024 Nov 12;19(11):e0312773. doi: 10.1371/journal.pone.0312773. eCollection 2024. PLoS One. 2024. PMID: 39531472 Free PMC article.

• Pyroglutamate Aβ cascade as drug target in Alzheimer's disease.

  Bayer TA. Bayer TA. Mol Psychiatry. 2022 Apr;27(4):1880-1885. doi: 10.1038/s41380-021-01409-2. Epub 2021 Dec 8. Mol Psychiatry. 2022. PMID: 34880449 Free PMC article. Review.

• Phosphine Catalyzed Michael-Type Additions: The Synthesis of Glutamic Acid Derivatives from Arylidene-α-amino Esters.

  Rodríguez-Flórez LV, González-Marcos M, García-Mingüens E, Retamosa MG, Kawase M, Selva E, Sansano JM. Rodríguez-Flórez LV, et al. Molecules. 2024 Jan 10;29(2):342. doi: 10.3390/molecules29020342. Molecules. 2024. PMID: 38257255 Free PMC article.

• Two-Dimensional Blue Native/SDS Polyacrylamide Gel Electrophoresis for Analysis of Brazilian Bothrops Snake Venoms.

  Ferreira de Oliveira N, Sachetto ATA, Santoro ML. Ferreira de Oliveira N, et al. Toxins (Basel). 2022 Sep 23;14(10):661. doi: 10.3390/toxins14100661. Toxins (Basel). 2022. PMID: 36287928 Free PMC article.

• Development and evolution of human glutaminyl cyclase inhibitors (QCIs): an alternative promising approach for disease-modifying treatment of Alzheimer's disease.

  Chen D, Chen Q, Qin X, Tong P, Peng L, Zhang T, Xia C. Chen D, et al. Front Aging Neurosci. 2023 Aug 3;15:1209863. doi: 10.3389/fnagi.2023.1209863. eCollection 2023. Front Aging Neurosci. 2023. PMID: 37600512 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Chemical Society

• Other Literature Sources

  • The Lens - Patent Citations Database
  • scite Smart Citations

• Chemical Information

  • BindingDB

• Molecular Biology Databases

  • Guide to Pharmacology

• Miscellaneous

  • NCI CPTAC Assay Portal